Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
30 Agosto 2024 - 3:39AM
UK Regulatory
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members,
executives and associated persons
Bagsværd, Denmark, 30 August 2024 — This
company announcement discloses the data of the transaction(s) made
in Novo Nordisk shares by the company’s board members, executives
and their associated persons in accordance with Article 19 of
Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated
persons have reported the transactions to Novo Nordisk and have
given Novo Nordisk power of attorney on their behalf to publish
trading in Novo Nordisk shares by the company’s board members,
executives and their associated persons.
Please find below a statement of such trading in shares issued
by Novo Nordisk.
|
|
Details of the person discharging managerial
responsibilities/person closely associated |
|
a) |
Name of the Board member/Executive/Associated Person |
Douglas Langa |
|
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Executive Vice President |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer |
|
|
a) |
Name |
Novo Nordisk A/S |
|
|
b) |
LEI |
549300DAQ1CVT6CXN342 |
|
|
4 |
Details of the transaction(s) |
|
|
a) |
Description of the financial instrument,
type of instrument, |
ADRs
|
|
|
|
Identification code |
NVO |
|
|
b) |
Nature of the transaction |
Purchase of ADRs |
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
DKK 904.41 |
12.742 ADRs |
|
|
|
|
DKK 904.35 |
4.047 ADRs |
|
|
|
|
|
|
|
|
|
d) |
Aggregated information
|
16.789 ADRs
DKK 15,183.93 |
|
|
e) |
Date of the transaction |
2024-08-28 |
|
|
f) |
Place of the transaction |
New York Stock Exchange |
|
Novo Nordisk is a leading global healthcare company, founded
in 1923 and headquartered in Denmark. Our purpose is to drive
change to defeat serious chronic diseases, built upon our heritage
in diabetes. We do so by pioneering
scientific breakthroughs, expanding access to our
medicines and working to prevent and ultimately cure disease. Novo
Nordisk employs about 69,000 people in 80 countries
and markets its products in around 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are
listed on the New York Stock Exchange (NVO). For
more information, visit
novonordisk.com, Facebook,
Instagram, X, LinkedIn
and YouTube.
Contacts for further information
|
Media: |
|
Ambre
James-Brown
+45 3079 9289
abmo@novonordisk.com
|
Liz
Skrbkova (US)
+1 609 917 0632
lzsk@novonordisk.com |
|
Investors: |
|
Jacob
Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com
|
David
Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com
|
Sina
Meyer
+45 3079 6656
azey@novonordisk.com
|
Mark
Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com
|
Ida Schaap
Melvold
+45 3077 5649
idmg@novonordisk.com |
Frederik
Taylor Pitter
+45 3075 8259
fptr@novonordisk.com |
Company announcement No 67 / 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Oct 2024 a Oct 2024
Novo Nordisk (TG:NOV)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
